Sales strategy, market reach and evidence-based medicine drives strong Orthobiologics performance
SmartTRAK reports that Q219 performance in the OrthoBio market was strong, up 6% YoY, exceeding SmartTRAK expectations. As expected, Medtronic was the overall OrthoBio market leader, followed by DePuy Synthes and Stryker. Overall, all OrthoBio technologies grew year-over-year except for Spinal Constructs, Soft Tissue Augmentation and Synthetic Cartilage. Although the Spine market has stabilized, Spinal Constructs continues to slowly lose share due to...
Among the many topics covered in the Q219 OrthoBio Market Recap* are:
- OrthoBio Market Highlights
- Comprehensive Market Overview
- Focused Sales Strategies are Paying Off
-
Market Access and Comps Do Impact Results
-
Demand Continues for Evidence-based Medicine (EBM)
-
Q219 Regulatory Highlights
Strategic sales tactics seem to be working for some companies, including pure play, pull through from enabling technologies and complementary acquisitions. These strategies are not only resulting in more cases, but also more revenue per case, which is off setting some negative trends like pricing declines, reduction in demand for legacy products and temporary tissue-related issues.
Based on review of YTD results and activities, market growth is being driven by several factors, including sales strategy, market reach with favorable comps and evidence-based medicine. These factors also may be behind growth in large cap and small/mid-cap ortho stocks, which are up...
*The entire article can only be viewed by SmartTRAK subscribers to this module. For information on how to subscribe, please click the button below.
